NCT02411344 - Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

January 12, 2018

Study Completion Date

January 12, 2018

Conditions

Endocrine Sensitive HER2+/HR+ Breast Cancer

Interventions

DRUG

Pertuzumab

"* Pertuzumab 840 mg loading dose iv on day one, followed by 420 mg iv every 3 weeks for 5 cycles~* Trastuzumab 8 mg/kg loading dose iv on day 2, followed by 6 mg/kg iv on day 2 of each subsequent 3 weekly cycle~* Letrozole 2.5 mg daily p.o. for five 21-day cycles (to be continued until surgery)."

Trial Locations (8)

35128

Istituto Oncologico Veneto, Oncologia Medica 2, Padua

Unknown

Policlinico Vittorio Emanuele, Catania

Arcispedale S. Anna, Cona

Istituto Europeo di Oncologia, Milan

Istituto Nazionale Tumori, Milan

"Ospedale Guglielmo da Saliceto", Piacenza

Arcispedale S. Maria Nuova, Reggio Emilia

A. O. U. Santa Maria della Misericordia, Udine

All Listed Sponsors

collaborator

Association for Translational Research in Oncology (AS.T.R.O.)

UNKNOWN

lead

Istituto Oncologico Veneto IRCCS

OTHER